DOCSLIB.ORG

Pilot Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of the Combination of Exemestane and Tamoxifen

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pilot Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of the Combination of Exemestane and Tamoxifen Vol. 10, 1943–1948, March 15, 2004 Clinical Cancer Research 1943 Pilot Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of the Combination of Exemestane and Tamoxifen Edgardo Rivera,1 Vicente Valero,1 pharmacokinetics or pharmacodynamics and that the com- Deborah Francis,1 Aviva G. Asnis,2 bination is well-tolerated and active. Further clinical inves- Larry J. Schaaf,2 Barbara Duncan,2 and tigation is warranted. Gabriel N. Hortobagyi1 1Department of Breast Medical Oncology, The University of Texas INTRODUCTION 2 M. D. Anderson Cancer Center, Houston, Texas, and Pharmacia Breast cancer growth frequently is promoted by estrogen, Corporation, Peapack, New Jersey and approximately one-third of tumors respond to estrogen deprivation therapy (1). In current clinical practice, two main ABSTRACT single-agent strategies are used to deprive breast cancer cells of Purpose: We conducted a pilot study assessing the ef- estrogen. A selective estrogen receptor modulator (SERM), such fects of the selective estrogen receptor modulator, tamox- as tamoxifen, is given to block binding of the hormone to the ifen, on the pharmacokinetics, pharmacodynamics, and cancer cells. Alternately, in postmenopausal women, an inhib- safety of the steroidal, irreversible aromatase inhibitor (AI), itor of the enzyme, aromatase, is administered to suppress their exemestane, when the two were coadministered in post- main source of estrogen synthesis, conversion of androgens by menopausal women with metastatic breast cancer. this enzyme. Experimental Design: Patients with documented or un- One aromatase inhibitor (AI) that has been studied exten- known hormone receptor sensitivity were eligible. Patients sively and shown activity as a single agent in postmenopausal received oral exemestane at 25-mg once daily. Starting day women with breast cancer is exemestane (Aromasin, Pharmacia 15, oral tamoxifen at 20-mg once daily, was added. We Corp., Peapack, NJ; Ref. 2–4). In contrast to other currently measured plasma concentrations of exemestane, estrone, es- approved AIs, which are nonsteroidal (type II) agents that tem- trone sulfate, and estradiol after 14 days of exemestane porarily inhibit aromatase activity, exemestane is a steroidal monotherapy and after ϳ4 weeks of combination therapy. (type I) agent that permanently inactivates the enzyme (5–7). As The incidence and severity of adverse events were assessed an androstenedione derivative, exemestane serves as a false by physical examination and patient reporting. substrate for aromatase. The drug is processed through the Results: We treated 18 patients. All had received prior normal catalytic mechanism to a transformed product, which chemotherapy and/or hormonal therapy, eight and six, re- binds covalently and irreversibly to the catalytic site of the spectively, with single-agent selective estrogen receptor enzyme (“suicide inhibition”). Resumption of estrogen produc- modulators or irreversible aromatase inhibitors; no hormo- tion depends on the synthesis of new aromatase molecules. nal therapy was given within 30 days of study entry. Plasma The separate and potentially complementary mechanisms exemestane concentrations and estrone, estrone sulfate, and of action of SERMs and AIs have prompted study of combina- estradiol suppression were unchanged after ϳ4 weeks of tion therapy of breast cancer with tamoxifen plus individual AIs. tamoxifen coadministration. All drug-related adverse events Initial investigation in a nude mouse model of breast carcinoma were grades 1 or 2; none was unexpected. Although not a suggested that coadministration of tamoxifen and either of the formal study end point, antitumor activity was noted, with nonsteroidal AIs, letrozole or anastrozole, provided no added two partial responses and four cases of stable disease among activity compared with single-agent use of these AIs (8). A pair 17 evaluable patients after a 9-month median follow-up of early pharmacokinetic and pharmacodynamic clinical studies (range, 2.5–19 months). showed that the combination of tamoxifen plus a nonsteroidal Conclusions: This pilot study provides evidence that AI at clinically recommended doses decreased mean plasma coadministration of tamoxifen does not affect exemestane concentrations of the AI relative to levels attained with single- agent therapy; for example, there was a decrease by 37.6% in the case of letrozole (9) and 27% in the case of anastrozole (10). However, both studies showed no effect of the addition of tamoxifen on the reduction in plasma estrogens effected by the Received 7/8/03; revised 11/10/03; accepted 12/5/03. nonsteroidal AIs. Grant support: Pharmacia Corporation, Peapack, NJ research grants. In contrast to the preclinical experience with tamoxifen The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked plus a nonsteroidal AI, an early study in rats with 7,12-dimeth- advertisement in accordance with 18 U.S.C. Section 1734 solely to ylbenzanthracene-induced mammary tumors showed that the indicate this fact. combination of exemestane plus tamoxifen had greater activity Requests for reprints: Edgardo Rivera, Department of Breast Medical than did either agent alone (11). On the basis of these results and Oncology, Unit 424, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009. Phone: on the demonstrated clinical efficacy of single-agent exemes- (713) 792-2817; Fax: (713) 794-4385; E-mail:erivera@mdanderson. tane (2–4) and tamoxifen (12) in this setting, we conducted a org. pilot study in postmenopausal women with metastatic breast Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2004 American Association for Cancer Research. 1944 Exemestane in Combination with Tamoxifen cancer to evaluate the pharmacokinetics, pharmacodynamics, ing tumor marker studies (cancer antigens 27–29 and carcino- and safety of exemestane when administered in combination embryonic antigen). Physical examination and all laboratory with tamoxifen. We now report the results of this trial. assessments were repeated every 8–12 weeks. Patients were told to report toxicities as any arose and were queried about adverse events during all follow-up visits. Toxicities were graded using PATIENTS AND METHODS the National Cancer Institute Common Toxicity Criteria, version Study End Points. To assess the pharmacokinetics of 2.0. Follow-up radiological evaluations were performed as re- exemestane when administered in combination with tamoxifen, quested by the primary physician. To verify compliance, pa- we measured plasma concentrations of exemestane after an tients were asked to bring their bottles of exemestane and initial period of single-agent administration and a subsequent tamoxifen on each follow-up visit and to document any missed period of combination therapy. To assess the pharmacodynam- doses. ics of exemestane in this setting, we performed similar meas- Patients continued on treatment until they had disease urements for plasma estrone (E1), estrone sulfate (E1S), and progression, became unable to tolerate or were noncompliant estradiol (E2). Additional endpoints were the incidence rate and with therapy, or withdrew consent. Patients were evaluated 4 grade of observed toxicities during the study, assessed by phys- weeks after their last dose of the combination and assessed for ical examination and patient reporting. any toxicities. We retrospectively plotted plasma exemestane concentra- Pharmacokinetic and Pharmacodynamic Measure- tion-time profiles after both the exemestane monotherapy and ments. Collection, storage, and processing of blood speci- exemestane plus tamoxifen combination therapy periods. In mens for pharmacokinetic and pharmacodynamic (i.e., estrogen) addition, we performed a retrospective statistical comparison of measurements were carried out according to specified proce- mean plasma estrogen values between these periods, with the dures. Briefly, blood samples were collected via venipuncture or study population serving as its own control. Compliance with an indwelling i.v. cannula on two occasions: at the end (day 14) and clinical response to therapy were not formal study end of the 2-week single-agent exemestane treatment period, and points but were recorded. after ϳ4 weeks of combination treatment (i.e., ϳ6 weeks after Eligibility Criteria and Ethical Considerations. Pa- the first dose of exemestane). These collection times were tients were eligible for the study if they had stage IV breast chosen in light of the published times to attain steady-state cancer with documented or unknown hormone receptor sensi- serum concentrations of 7 days for exemestane and 3–4 weeks tivity, were postmenopausal, and were candidates for hormonal for tamoxifen given as single agents at the doses used in our therapy. Patients who had received single-agent tamoxifen or study (7, 14). For exemestane pharmacokinetic measurements, AIs in the adjuvant or metastatic setting were eligible, as long as ϳ5 ml of venous whole blood was obtained before (0 h) and 1, these drugs had not been given within 21 days of study entry. 2, 4, 6, 8, and 24 h after dosing. For pharmacodynamic meas- Patients were required to have measurable or evaluable disease, urements, a single 16-ml venous whole blood specimen was a life expectancy Ն12 weeks and a Zubrod performance status obtained on the mornings of the two collection occasions (pos- (13) Յ1. Other eligibility criteria
Load more

Recommended publications
  • Prospective Study on Gynaecological Effects of Two Antioestrogens Tamoxifen and Toremifene in Postmenopausal Women
    British Journal of Cancer (2001) 84(7), 897–902 © 2001 Cancer Research Campaign doi: 10.1054/ bjoc.2001.1703, available online at http://www.idealibrary.com on http://www.bjcancer.com Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women MB Marttunen1, B Cacciatore1, P Hietanen2, S Pyrhönen2, A Tiitinen1, T Wahlström3 and O Ylikorkala1 1Departments of Obstetrics and Gynecology, Helsinki University Central Hospital, P.O. Box 140, FIN-00029 HYKS, Finland; 2Department of Oncology, Helsinki University Central Hospital, P.O. Box 180, FIN-00029 HYKS, Finland; 3Department of Pathology, Helsinki University Central Hospital, P.O. Box 140, FIN-00029 HYKS, Finland Summary To assess and compare the gynaecological consequences of the use of 2 antioestrogens we examined 167 postmenopausal breast cancer patients before and during the use of either tamoxifen (20 mg/day, n = 84) or toremifene (40 mg/day, n = 83) as an adjuvant treatment of stage II–III breast cancer. Detailed interview concerning menopausal symptoms, pelvic examination including transvaginal sonography (TVS) and collection of endometrial sample were performed at baseline and at 6, 12, 24 and 36 months of treatment. In a subgroup of 30 women (15 using tamoxifen and 15 toremifene) pulsatility index (PI) in an uterine artery was measured before and at 6 and 12 months of treatment. The mean (±SD) follow-up time was 2.3 ± 0.8 years. 35% of the patients complained of vasomotor symptoms before the start of the trial. This rate increased to 60.0% during the first year of the trial, being similar among patients using tamoxifen (57.1%) and toremifene (62.7%).
    [Show full text]
  • Tamoxifen, Raloxifene Upheld for Prevention
    38 WOMEN’S HEALTH MAY 1, 2010 • FAMILY PRACTICE NEWS Tamoxifen, Raloxifene Upheld for Prevention BY KERRI WACHTER 9,736 on tamoxifen and 9,754 on ralox- 1.24, which was significant (P = .01). Both events) did not appear to be as effective ifene. The differences in numbers are due drugs reduced the risk of invasive breast as tamoxifen (57 events) in preventing WASHINGTON — Tamoxifen and to a combination of loss during follow- cancer by roughly 50% in the original re- noninvasive breast cancer (P = .052). raloxifene offer women at high risk of up or follow-up data becoming available port (median follow-up 47 months). “Now with additional follow-up, those developing breast cancer two effective for women who were lost to follow-up “We have estimated, however, that differences have narrowed,” he said. At options to prevent the disease, based on in the original report. Women on ta- this difference in the raloxifene-treated 8 years, there was no statistical signifi- 8 years of follow-up data for more than moxifen received 20 mg/day and those group represents 76% of tamoxifen’s cance between the two groups with a 19,000 women in the STAR trial. on raloxifene received 60 mg/day. chemopreventative benefit, which trans- risk ratio of 1.22 (P = .12). The relative While tamoxifen proved significantly At an average follow-up of 8 years, the lates into at 38% reduction in invasive risk of 1.22 favors tamoxifen, but ralox- more effective in preventing invasive breast relative risk of invasive breast cancer on breast cancers,” Dr.
    [Show full text]
  • Effects of Biologically Active Metabolites of Tamoxifen on the Proliferation Kinetics of MCF-7 Human Breast Cancer Cells in Vitro
    [CANCER RESEARCH 43, 4618-4624, October 1983] Effects of Biologically Active Metabolites of Tamoxifen on the Proliferation Kinetics of MCF-7 Human Breast Cancer Cells in Vitro Roger R. Reddel, Leigh C. Murphy, and Robert L. Sutherland1 Ludwig Institute for Cancer Research (Sydney Branch), University of Sydney, Sydney, New South Wales 2006, Australia ABSTRACT tumor tissues of patients treated with tamoxifen is DMT, with 4OHT being present at much lower concentrations (1, 7,13, 25). The effects of two major metabolites of tamoxifen, /V-de- Prompted no doubt in part by the early misidentification of the methyltamoxifen (DMT) and 4-hydroxytamoxifen (4OHT), on major metabolite as 4OHT, there has been considerable interest MCF-7 Å“il proliferation and cell cycle kinetic parameters were in the antiestrogenic and antitumor activity of 4OHT (2, 3, 6,15, compared with those of the parent compound. All three com 16, 33). In contrast, there have been very few studies on the pounds produced dose-dependent decreases in the rate of cell biological activity of DMT (6, 33). proliferation which were accompanied by decreases in the per In the present study, we have attempted to answer the follow centage of S- and G2-M-phase cells. 4OHT was 100- to 167-fold ing questions. Do the metabolites DMT and 40HT differ from more potent than both tamoxifen and DMT in producing these tamoxifen in their actions on the proliferation and cell cycle effects, and this was correlated with their relative binding affini kinetics of human breast cancer cells? What are the relative ties (RBAs) for the cytoplasmic estrogen receptor (ER) (17/3- potencies of these 3 compounds in their actions on such cells in estradiol = 100, 4OHT = 41, tamoxifen = DMT = 2).
    [Show full text]
  • Chemotherapy Regimen: Tamoxifen
    Tamoxifen Chemotherapy Teaching The Center for Breast Cancer Mass General Cancer Center Center for Breast Cancer Topics to Discuss: • How Tamoxifen works • How Tamoxifen is taken • Storage, Handling, and Disposal • Drug Interactions • Side Effects & How to Manage • Supportive Care Resources • Your Breast Cancer Team • When to Call • Important Phone Numbers 2 What is TAMOXIFEN? • TAMOXIFEN (Nolvadex®) is an oral hormonal therapy used for hormone-sensitive breast cancers. • It works by blocking estrogen from binding to hormone receptors. This: • decreases the chance of breast cancer returning (recurrence) • decreases tumor size • delays tumors from spreading (progression) • Your care team will talk with you about how long you will need to take this therapy. – It is common to be on therapy for 5-10 years. 3 How is it taken? • TAMOXIFEN is a tablet you take by mouth. • Take one tablet (20 mg) once daily with or without food at the same time each day. – Do not take with grapefruit juice. • Swallow tablet whole with water. Do not break, chew, or crush your tablet. • If you miss a dose, skip the dose. Do not take 2 doses at the same time to make up for the missed dose. 4 Storing and Handling • Keep TAMOXIFEN in its original bottle or in a separate pill box – do not mix other medicines into the same pill box. • Store at room temperature in a dry location away from direct light. • Keep out of reach from children and pets. • Wash your hands before and after handling. – If someone else will be handling your TAMOXIFEN, have them wear gloves so they do not come into direct contact with the medicine.
    [Show full text]
  • Pharmacogenomics of Endocrine Therapy in Breast Cancer
    Journal of Human Genetics (2013) 58, 306–312 & 2013 The Japan Society of Human Genetics All rights reserved 1434-5161/13 OPEN www.nature.com/jhg REVIEW Pharmacogenomics of endocrine therapy in breast cancer James N Ingle The most important modality of treatment in the two-thirds of patients with an estrogen receptor (ER)-positive early breast cancer is endocrine therapy. In postmenopausal women, options include the selective ER modulators (SERMs), tamoxifen and raloxifene, and the ‘third-generation’ aromatase inhibitors (AIs), anastrozole, exemestane and letrozole. Under the auspices of the National Institutes of Health Global Alliance for Pharmacogenomics, Japan, the Mayo Clinic Pharmacogenomics Research Network Center and the RIKEN Center for Genomic Medicine have worked collaboratively to perform genome-wide association studies (GWAS) in women treated with both SERMs and AIs. On the basis of the results of the GWAS, scientists at the Mayo Clinic have proceeded with functional genomic laboratory studies. As will be seen in this review, this has led to new knowledge relating to endocrine biology that has provided a clear focus for further research to move toward truly personalized medicine for women with breast cancer. Journal of Human Genetics (2013) 58, 306–312; doi:10.1038/jhg.2013.35; published online 2 May 2013 Keywords: aromatase inhibitors; breast cancer; pharmacogenomics; tamoxifen INTRODUCTION trials were the double-blind, placebo-controlled NSABP P-1 trial of Breast cancer is the most common form of cancer in women both in tamoxifen8, and the double-blind NSABP P-2 trial that compared the United States1 and Japan.2 Endocrine therapy is the most raloxifene with tamoxifen.9,10 Combined, these two studies involved important modality in the two-thirds of patients with an estrogen over 33 000 women, which constituted about 59% of the world’s receptor (ER)-positive early breast cancer.
    [Show full text]
  • Aromatase Inhibitors
    FACTS FOR LIFE Aromatase Inhibitors What are aromatase inhibitors? Aromatase Inhibitors vs. Tamoxifen Aromatase inhibitors (AIs) are a type of hormone therapy used to treat some breast cancers. They AIs and tamoxifen are both hormone therapies, are taken in pill form and can be started after but they act in different ways: surgery or radiation therapy. They are only given • AIs lower the amount of estrogen in the body to postmenopausal women who have a hormone by stopping certain hormones from turning receptor-positive tumor, a tumor that needs estrogen into estrogen. If estrogen levels are low to grow. enough, the tumor cannot grow. AIs are used to stop certain hormones from turning • Tamoxifen blocks estrogen receptors on breast into estrogen. In doing so, these drugs lower the cancer cells. Estrogen is still present in normal amount of estrogen in the body. levels, but the breast cancer cells cannot get enough of it to grow. Generic/Brand names of AI’s As part of their treatment plan, some post- Generic name Brand name menopausal women will use AIs alone. Others anastrozole Arimidex will use tamoxifen for 1-5 years and then begin exemestane Aromasin using AIs. letrozole Femara Who can use aromatase inhibitors? Postmenopausal women with early stage and metastatic breast cancer are often treated with AIs. After menopause, the ovaries produce only a small amount of estrogen. AIs stop the body from making estrogen, and as a result hormone receptor-positive tumors do not get fed by estrogen and die. AIs are not given to premenopausal women because their ovaries still produce estrogen.
    [Show full text]
  • The Role of the Androgen Receptor Signaling in Breast Malignancies PANAGIOTIS F
    ANTICANCER RESEARCH 37 : 6533-6540 (2017) doi:10.21873/anticanres.12109 Review The Role of the Androgen Receptor Signaling in Breast Malignancies PANAGIOTIS F. CHRISTOPOULOS*, NIKOLAOS I. VLACHOGIANNIS*, CHRISTIANA T. VOGKOU and MICHAEL KOUTSILIERIS Department of Experimental Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece Abstract. Breast cancer (BrCa) is the most common decades, BrCa still has a poor prognosis with 5-year survival malignancy among women worldwide, and one of the leading rates of metastatic disease reaching to 26% only. BrCa is the causes of cancer-related deaths in females. Despite the second leading cause of death among female cancers with development of novel therapeutic modalities, triple-negative 40,610 estimated deaths in the U.S. expected in 2017 (1). breast cancer (TNBC) remains an incurable disease. Androgen Breast cancer comprises a heterogeneous group of diseases receptor (AR) is widely expressed in BrCa and its role in the with variable course and outcome. Currently, BrCa is sub- disease may differ depending on the molecular subtype and the classified into distinct molecular subtypes named: normal stage. Interestingly, AR has been suggested as a potential target breast like, luminal A/B, HER-2 related, basal-like and claudin- candidate in TNBC, while sex hormone levels may regulate the low (2, 3). Estrogen receptor (ER), progesterone receptor (PR) role of AR in BrCa subtypes. In the presence of estrogen and HER2 have long been established as useful prognostic and receptor α ( ERa ), AR may antagonize the ER α- induced effects, predictive biomarkers. Hormonal therapy in ER and PR whereas in the absence of estrogens, AR may act as an ER α- positive tumors (4), as well as the use of monoclonal antibodies mimic, promoting tumor.
    [Show full text]
  • Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy † EVAN R
    Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy † EVAN R. SIMPSON* AND MITCH DOWSETT *Prince Henry’s Institute of Medical Research, Monash Medical Centre, Clayton, Victoria 3168, Australia; †Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom ABSTRACT Endocrine adjuvant therapy for breast cancer in recent years has focussed primarily on the use of tamoxifen to inhibit the action of estrogen in the breast. The use of aromatase inhibitors has found much less favor due to poor efficacy and unsustainable side effects. Now, however, the situation is changing rapidly with the introduction of the so-called phase III inhibitors, which display high affinity and specificity towards aromatase. These compounds have been tested in a number of clinical settings and, almost without exception, are proving to be more effective than tamoxifen. They are being approved as first-line therapy for elderly women with advanced disease. In the future, they may well be used not only to treat young, postmenopausal women with early-onset disease but also in the chemoprevention setting. However, since these compounds inhibit the catalytic activity of aromatase, in principle, they will inhibit estrogen biosynthesis in every tissue location of aromatase, leading to fears of bone loss and possibly loss of cognitive function in these younger women. The concept of tissue-specific inhibition of aromatase expression is made possible by the fact that, in postmenopausal women when the ovaries cease to produce estrogen, estrogen functions primarily as a local paracrine and intracrine factor. Furthermore, due to the unique organization of tissue-specific promoters, regulation in each tissue site of expression is controlled by a unique set of regulatory factors.
    [Show full text]
  • Ribociclib (LEE011)
    Clinical Development Ribociclib (LEE011) Oncology Clinical Protocol CLEE011G2301 (EarLEE-1) / NCT03078751 An open label, multi-center protocol for U.S. patients enrolled in a study of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2- negative, high risk early breast cancer Authors Document type Amended Protocol Version EUDRACT number 2014-001795-53 Version number 02 (Clean) Development phase II Document status Final Release date 17-Apr-2018 Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis Template version 22-Jul-2016 Novartis Confidential Page 2 Amended Protocol Version 02 (Clean) Protocol No. CLEE011G2301 Table of contents Table of contents ................................................................................................................. 2 List of tables ........................................................................................................................ 5 List of abbreviations ............................................................................................................ 6 Glossary of terms ................................................................................................................. 9 Protocol summary .............................................................................................................. 10 Amendment 2 (17-Apr-2018) ............................................................................................ 14
    [Show full text]
  • Effect of Tamoxifen Or Anastrozole on Steroid Sulfatase Activity and Serum Androgen Concentrations in Postmenopausal Women with Breast Cancer
    ANTICANCER RESEARCH 31: 1367-1372 (2011) Effect of Tamoxifen or Anastrozole on Steroid Sulfatase Activity and Serum Androgen Concentrations in Postmenopausal Women with Breast Cancer S.J. STANWAY1, C. PALMIERI2, F.Z. STANCZYK3, E.J. FOLKERD4, M. DOWSETT4, R. WARD2, R.C. COOMBES2, M.J. REED1† and A. PUROHIT1 1Oncology Drug Discovery Group, Section of Investigative Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, U.K.; 2Cancer Research UK Laboratories, Department of Oncology, Hammersmith Hospital, London W12 0NN, U.K.; 3Reproductive Endocrine Research Laboratory, University of Southern California, Keck School of Medicine, Women’s and Children’s Hospital, Los Angeles, CA, U.S.A.; 4Department of Biochemistry, Royal Marsden Hospital, London, SW3 6JJ, U.K. Abstract. Background: In postmenopausal women sulfate and dehydroepiandrosterone levels. Results: Neither estrogens can be formed by the aromatase pathway, which anastrozole nor tamoxifen had any significant effect on STS gives rise to estrone, and the steroid sulfatase (STS) route activity as measured in PBLs. Anastrozole did not affect which can result in the formation of estrogens and serum androstenediol concentrations. Conclusion: androstenediol, a steroid with potent estrogenic properties. Anastrozole and tamoxifen did not inhibit STS activity and Aromatase inhibitors, such as anastrozole, are now in serum androstenediol concentrations were not reduced by clinical use whereas STS inhibitors, such as STX64, are still aromatase inhibition. As androstenediol has estrogenic undergoing clinical evaluation. STX64 was recently shown properties, it is possible that the combination of an to block STS activity and reduce serum androstenediol aromatase inhibitor and STS inhibitor may give a therapeutic concentrations in postmenopausal women with breast cancer.
    [Show full text]
  • Aromatase Inhibitors and Their Use in the Sequential Setting
    Endocrine-Related Cancer (1999) 6 259-263 Aromatase inhibitors and their use in the sequential setting R C Coombes, C Harper-Wynne1 and M Dowsett1 Cancer Research Campaign, Department of Cancer Medicine, Division of Medicine, Imperial College School of Medicine, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK 1Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK (Requests for offprints should be addressed to R C Coombes) Abstract Over the past decade several novel aromatase inhibitors have been introduced into clinical practice. The discovery of these drugs followed on from the observation that the main mechanism of action of aminogluthemide was via inhibition of the enzyme aromatase thereby reducing peripheral levels of oestradiol in postmenopausal patients. The second-generation drug, 4-hydroxyandrostenedione (formestane), was introduced in 1990 and although its use was limited by its need to be given parenterally it was found to be a well-tolerated form of endocrine therapy. Third-generation inhibitors include vorozole, letrozole, anastrozole and exemestane, the former three being non-steroidal inhibitors, the latter being a steroidal inhibitor. All are capable of inhibiting aromatase action by >95% compared with 80% in the case of 4-hydroxyandrostenedione. The sequential use of different generations of aromatase inhibitors in the same patients is discussed. Studies suggest that an optimal sequence of these compounds may well result in longer remission in patients with hormone receptor positive tumours. Endocrine-Related Cancer (1999) 6 259-263 Introduction reduced, although formal trials comparing different dose regimens and using sufficient numbers of patients to The aromatase enzyme is a cytochrome P450-mediated provide the necessary statistical power have not been enzyme complex responsible for the conversion of the adequately carried out.
    [Show full text]
  • Toremifene (Fareston)
    Clinical Policy: Toremifene (Fareston) Reference Number: PA.CP.PMN.126 Effective Date: 10.17.18 Last Review Date: 04.17.19 Revision Log Description Toremifene (Fareston®) is an estrogen agonist/antagonist. FDA Approved Indication(s) Fareston is indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with PA Health & Wellness® that Fareston is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Breast Cancer (must meet all): 1. Diagnosis of recurrent or metastatic breast cancer; 2. Prescribed by or in consultation with an oncologist; 3. Failure of a 1-month trial of tamoxifen at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced; 4. Failure of a 1-month trial of an aromatase inhibitor (e.g., anastrozole, exemestane, letrozole) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced (see Appendix B); 5. Request meets one of the following (a or b): a. Dose does not exceed 60 mg per day (1 tablet/day); b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence). Approval duration: 12 months B. Soft Tissue Sarcoma - Desmoid Tumors (off-label) (must meet all): 1. Diagnosis of desmoid tumor or aggressive fibromatosis; 2. Prescribed by or in consultation with an oncologist; 3.
    [Show full text]